TXA was first found to reduce maternal morbidity at time of established postpartum hemorrhage in the WOMAN trial (2017). Since then, evidence has grown to include TXA as a prophylactic agent to prevent postpartum hemorrhage. Despite its known effectiveness in BOTH the prevention and treatment of postpartum hemorrhage, there is a renewed global warning regarding this medication. In this episode, we will review the WHO and FDA warning regarding the misapplication/inadvertent intrathecal use of TXA at time of cesarean section.
